Ceftolozane/tazobactam (C/T) is a novel cephalosporin and β-lactamase inhibitor combination with great activity against Pseudomonas aeruginosa. To assess P. aeruginosa susceptibility to C/T, a surveillance study was conducted from October 2018 to March 2019 at the University Hospital 'Ospedali Riuniti' in Ancona, Italy.
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy / Morroni, G., Brescini, L., Antonelli, A., Di Pilato, V., Castelletti, S., Brenciani, A., D'Achille, G., Mingoia, M., Giovanetti, E., Fioriti, S., Masucci, A., Giani, T., Giacometti, A., Rossolini, G.M., Cirioni, O.. - In: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE. - ISSN 2213-7173. - ELETTRONICO. - 30:(2022), pp. 377-383. [10.1016/j.jgar.2022.07.010]
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
Antonelli, Alberto;Di Pilato, Vincenzo;Giani, Tommaso;Rossolini, Gian Maria;
2022
Abstract
Ceftolozane/tazobactam (C/T) is a novel cephalosporin and β-lactamase inhibitor combination with great activity against Pseudomonas aeruginosa. To assess P. aeruginosa susceptibility to C/T, a surveillance study was conducted from October 2018 to March 2019 at the University Hospital 'Ospedali Riuniti' in Ancona, Italy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S221371652200176X-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
727 kB
Formato
Adobe PDF
|
727 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
